In patients with TGs >150 mg/dL and high CV risk, apoC-III inhibitor olezarsen reduced TG levels by ~50%. Olezarsen also reduced apoB and non-HDL-C, markers of atherogenic risk. Proud to be a part of this team. Full paper now in @NEJM. @TIMIStudyGroup @BrianBergmark

RT @sameralsaid: Factor XI inhibition with abelacimab may be particularly attractive in AF patients with concomitant antiplatelet therapy.….

RT @YumiKangEndo: Clinical benefit of PCK9i inhibition in people with T1DM - Manuscript can be found at

RT @TIMIStudyGroup: Beyond the❤️: GLP-1 RAs also reduce non-CV mortality. Meta-analysis of 11 CVOTs (n=90,867) shows ↓ in all-cause, CV, an….

RT @FedericaFogacci: Great to meet up w/ EAS YF at #EASCongress2025! Always inspiring to connect w/ colleagues 🌍, and honored to have Profs….

RT @TIMIStudyGroup: Coverage in @JWatch of @AndreZimerman's analysis of #evolocumab in patients in FOURIER TIMI 59 with autoimmune or infla….

RT @Bweber04: Thrilled to be a part of this study led by superstar 🌟@AndreZimerman in @CircAHA 👇! FOURIER analysis, PCSK9i in systemic infl….

RT @CircAHA: Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with auto….

In summary:. 1. Intensive LDL-C lowering with evolocumab may lead to greater CV event reduction in patients with autoimmune or inflammatory diseases. 2. Findings support consideration of more aggressive lipid lowering in pts with autoimmune or inflammatory diseases. (10/10).

The most interesting takeaway:. “(…) the increased risk attributable to inflammation can potentially be mitigated by intensive lipid-lowering alone.”. Many mechanistic questions remain to be tested. (9/10)

Interestingly, when LLTs were used in patients with inflammatory conditions, the relative reductions in MACE and myocardial infarction were significantly greater than expected from LDL-lowering alone. (8/10)

“But André, this is just an exploratory subgroup analysis. What other evidence supports the idea of a stronger CV benefit with lipid-lowering in patients with AIID?”. We conducted a systematic review and trial-level meta-regression to find out. (7/10).

This trend was consistent across multiple endpoints, although analyses were very underpowered for individual endpoints. ARRs were ~3-fold greater in patients with AIID, resulting in NNTs of ≤17 to prevent 1 primary or key secondary endpoint at 3 yrs. (6/10)

This is not what happened. Intensive LDL-C lowering with evolocumab led to greater relative and absolute reductions in CV events in patients with AIID (right) compared with those without AIID (left). (5/10)

In FOURIER, 889 patients had an AIID at baseline. LDL-C levels and changes with evolocumab were comparable in pts with or without AIID. hsCRP was unchanged. If relative reductions in CV events were simply related to LDL-C, the CV benefit by AIID status should be similar. (4/10).

PCSK9 inhibitors, like evolocumab, lack any clear effect on systemic markers of inflammation such as hsCRP. It’s unclear if patients with AIID would respond differently to evolocumab. We sought to find out. (3/10).

Patients with autoimmune or inflammatory diseases (AIID) have a higher CV risk. These patients also seem to have a greater *relative* benefit from statins, perhaps due to their anti-inflammatory effect. What about PCSK9 inhibitors? (2/10).

Does the CV benefit of evolocumab differ in patients with autoimmune or inflammatory diseases?. The answer lies at the intersection of dyslipidemia and inflammation. A 🧵 on our new Circulation paper. (1/10). Link: @TIMIStudyGroup @rgiugliano

RT @marstonMD: Now out in @NatureMedicine, we developed an Endothelial Cell PRS for CAD that:. 1) Quantifies a currently immeasurable axis….

RT @sameralsaid: There doesn’t appear to be a floor with LDL—💥 lower is better, even in the elderly. Check out our work in @JACCJournals h….

RT @NEJMEvidence: In this study of 473 patients, very low levels of LDL achieved via PCSK9 inhibitors was not associated with cognitive dec….